These findings suggest that genetically modified MSCs capable of delivering IL-7 and IL-12 to the tumor site can effectively modulate the tumor microenvironment by promoting Th1 cell-driven immune response that supports CAR T cell activity [28]. The gene discussed is IL7; the disease is neoplasm.